For most of its public life, Vericel lost money while growing fast. It sells two unusual things: living skin grafts for severe burn patients, and cartilage repair implants for athletes with damaged knees. Neither product is cheap to make, and neither sells itself. For years, the revenue climbed while the losses mounted, and the stock rewarded the growth and ignored the red ink. Then something changed.
The change shows up starkly in two numbers that sit side by side in the filings and do not quite fit together. The 10-K for fiscal year 2025 shows a net margin of 6%, the highest in the company’s recent history, on revenue of $276 million. The stock, at $41.09 as of our data, sits meaningfully below its 52-week high. A business earning more per dollar of sales than it ever has is being valued more cautiously than it was when it earned almost nothing. That gap is the story.
What matters here
Filed numbers show Vericel has crossed from chronic losses into consistent, expanding profit: net margin went from negative territory in 2021 and 2022 to solidly positive by 2024 and higher still in 2025, while revenue has grown at double digits for three straight years. The stock’s price-to-sales ratio sits in the bottom 11th percentile of its own decade range, according to our data, meaning the market is paying less relative to sales than it has almost any time in ten years. The open question is whether the market is correctly skeptical of how long this profitability holds, or whether it is simply slow to update.
How a money-loser became a money-maker
The arc matters here. In 2021 and 2022, Vericel was spending heavily to build out its sales force and expand the market for its two main products, MACI (the cartilage implant) and Epicel (the burn graft). Revenue grew, but losses widened. The 10-K for fiscal year 2023 showed the first sign of a turn: revenue jumped sharply and the net loss shrank to nearly nothing. By the 10-K for fiscal year 2024, the company posted its first meaningful profit in years.
The 2025 annual filing extends that pattern. Revenue reached $276 million, earnings per share rose to $0.32, and the net margin expanded again. Think of it like a restaurant that spent five years building its kitchen and training its staff at a loss, then watched the same fixed costs support a growing number of covers. Each additional dollar of revenue costs less to produce than the last, and the profit line grows faster than the top line. That is what the filed numbers describe.
The profitability improvement is not a one-year event. It has compounded across three consecutive filings, a pattern the filed numbers make legible across the full arc.
The most recent quarter, and what comes tomorrow
The 10-Q for the quarter ended June 30, 2026 shows revenue of $77.5 million, up sharply from the same quarter a year earlier, according to MarketBeat’s earnings tracker. The company earned a small profit per share in a quarter that analysts had expected to produce a small loss. That is a meaningful beat, not a rounding error.
One caution: the dossier research did not return Vericel-specific data on gross margin or operating expense trends for the most recent quarter, so we cannot say with precision how much of the revenue gain fell through to profit. The data cannot answer that here, and we say so plainly.
Q3 2026 results, scheduled for November 5, 2026 per MarketBeat’s earnings calendar, represent the next scheduled update to the filed record.
Reading the numbers
- Revenue, FY2025: $276 million, up 16.5% from 2024. What it is: total sales for the year. What it means here: Vericel has now grown revenue at 16% or better for three consecutive years, a pace roughly four times faster than the broad economy. Worked example: a business growing at this rate doubles in size roughly every four to five years, all else equal.
- Net margin, FY2025: 6%. What it is: the share of each dollar of sales left after every bill is paid. What it means here: in 2022, this number was negative 10%, meaning the company lost a dime on every dollar it took in. Three years later it keeps six cents. That is a 16-cent swing per dollar of revenue. Worked example: on $276 million in sales, the difference between a negative-10% margin and a positive-6% margin is roughly $44 million in profit, more than the company earned in total revenue a decade ago.
- Price-to-sales ratio: 7.5 times, 11th percentile of own decade. What it is: the price tag the market puts on each dollar of annual sales (a multiple, meaning the price per unit of a financial measure). What it means here: the market has almost never valued this company’s sales more cheaply, relative to its own history. That is either a signal that something has genuinely deteriorated, or that the mood (what the market currently pays) has not caught up to the math (what the filed fundamentals show). Worked example: IF the multiple were to revert to its decade median of 10.3 times and IF revenue held near current levels, the same arithmetic would point to a market value of roughly $1,030 on that same $100 of sales, a scenario, not a forecast.
- Q2 2026 revenue: $77.5 million, up 22.5% year over year. What it is: the most recent quarterly sales figure from the June 2026 10-Q. What it means here: the growth rate in the most recent quarter accelerated above the full-year 2025 pace of 16.5%, suggesting the business did not slow entering 2026. Worked example: at this quarterly pace, annualized revenue would run above $300 million, a threshold the company has never crossed.
Sources
- 10-Q for quarter ended 2026-06-30 (SEC EDGAR)
- 10-K for fiscal year ended 2025-12-31 (SEC EDGAR)
- 10-K for fiscal year ended 2024-12-31 (SEC EDGAR)
- 10-K for fiscal year ended 2023-12-31 (SEC EDGAR)
- MarketBeat: VCEL earnings history and estimates
- MarketBeat: Q3 2026 earnings date confirmation
